(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

Dr Reddy's shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay ...

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

Dr Reddy's Laboratories share price plunged 6.66 per cent at Rs 1,203.50 per share on the NSE in Friday's intraday deals after analysts remained cautious on the company's Q3 performance ...

The company's North American revenue has seen a decline of over 9%. One of the primary worries is the reduction in revenues ...

Revlimid has arguably been the single biggest growth driver for Dr Reddy's in recent years, fueling record-high US sales last ...

Although Dr Reddy's Laboratories' Q3 earnings slightly exceeded analysts' expectations, the main point of concern was the ...

Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

Indian shares closed lower on Friday after a choppy session. Markets gave up early gains as concerns about slowing earnings growth ...

Indian shares were subdued on Friday after U.S. President Donald Trump reiterated his firm stance on tariffs. At the World Economic ...